Positions

Principal Investigator On

  • HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial  awarded by CHILDREN'S HEALTHCARE OF ATLANTA
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB (SOBI, INC)
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Project Sickle Cure  awarded by CHILDREN'S HEALTHCARE OF ATLANTA
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • Reduced-Intensity Conditioning for Children and Adults with Hemaphagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia.  awarded by National Marrow Donor Program
  • Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogenic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Severe Sickle Cell Disease: A Pilot Study  awarded by Emory University
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 0601  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 601  awarded by NATIONAL CHILDHOOD CANCER FOUNDATION

    • Investigator On

  • 11-TREO: A Phase II Study of Treosulfane/Fiudarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children with AMLIMDS Undergoing Allogeneic Hematopoietic Cell Transplantation  awarded by National Marrow Donor Program
  • A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients  awarded by New York Blood Center
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders/ PBMTC PIDTC #6901  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRaß+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801  awarded by Childrens Hospital Los Angeles
  • A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317  awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ACTION Trial- Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-Diagnosed Pediatric High-Grade Gliomas (Phase I)  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • Acute GVHD Suppression using Co-Stimulation Blockage to Expand Non-Malignant Transplant (ASCENT)  awarded by Emory University
  • Acute GVHD Suppression using Costimulation Blockage to Expand Non-malignant Transplant (ASCENT)  awarded by Emory University
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Identifying Predictors of Poor Health Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors  awarded by National Marrow Donor Program
  • PBMTC Study No. 1701 "Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children with B-ALL (Endrad) Trial"  awarded by CHILDREN'S HOSPITAL LA
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Predictive Biomarkers of Pediatric Graft-Versus-Host Disease  awarded by Canadian Institutes of Health Research
  • Primary Immune Deficiency Treatment Consortium  awarded by University of California, San Francisco
  • Primary Immune Deficiency Treatment Consortium  awarded by University of California, San Francisco
  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by ALLOVIR INC.
  • Private Grant  awarded by KADMON CORPORATION
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)

    • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • Cincinnati Children's Medical Center, Postdoctoral Fellowship
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Louisiana State University System : University of New Orleans 2004
  • Bachelor of Science or Mathematics in Microbiology, Louisiana State University System : Baton Rouge 2000

    • Full Name

  • Hilary Haines